News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
84,565 Results
Type
Article (2673)
Company Profile (20)
Press Release (81871)
Multimedia
Podcasts (2)
Webinars (3)
Section
Business (25427)
Career Advice (29)
Deals (5129)
Drug Delivery (2)
Drug Development (10315)
Employer Resources (3)
FDA (2032)
Job Trends (1070)
News (43521)
Policy (3907)
Tag
Academia (134)
Accelerated approval (4)
Adcomms (5)
Allergies (21)
Alliances (9176)
ALS (13)
Alzheimer's disease (168)
Antibody-drug conjugate (ADC) (78)
Approvals (2130)
Artificial intelligence (32)
Autoimmune disease (16)
Automation (1)
Bankruptcy (12)
Best Places to Work (797)
BIOSECURE Act (5)
Biosimilars (64)
Biotechnology (19)
Bladder cancer (28)
Brain cancer (7)
Breast cancer (54)
Cancer (594)
Cardiovascular disease (27)
Career advice (22)
CAR-T (26)
CDC (1)
Cell therapy (101)
Cervical cancer (3)
Clinical research (9138)
Collaboration (294)
Compensation (50)
Complete response letters (9)
COVID-19 (290)
CRISPR (7)
C-suite (100)
Cystic fibrosis (7)
Data (731)
Depression (12)
Diabetes (42)
Diagnostics (648)
Digital health (4)
Drug discovery (37)
Drug pricing (2)
Duchenne muscular dystrophy (29)
Earnings (9256)
Editorial (2)
Employer resources (3)
Events (9734)
Executive appointments (108)
FDA (2476)
Fibrodysplasia Ossificans Progressiva (2)
Frontotemporal dementia (1)
Funding (164)
Gene editing (17)
Generative AI (1)
Gene therapy (67)
GLP-1 (79)
Government (284)
Grass and pollen (1)
Guidances (44)
Healthcare (1451)
HIV (1)
Huntington's disease (2)
IgA nephropathy (18)
Immunology and inflammation (18)
Immuno-oncology (5)
Indications (12)
Infectious disease (306)
Inflammatory bowel disease (34)
Inflation Reduction Act (1)
Influenza (11)
Intellectual property (38)
Interviews (6)
IPO (1966)
Job creations (303)
Job search strategy (19)
JPM (5)
Kidney cancer (1)
Labor market (5)
Layoffs (26)
Legal (1011)
Liver cancer (20)
Lung cancer (104)
Lymphoma (56)
Machine learning (1)
Management (2)
Manufacturing (109)
MASH (13)
Medical device (1226)
Medtech (1233)
Mergers & acquisitions (3349)
Metabolic disorders (88)
Multiple sclerosis (16)
NASH (1)
Neurodegenerative disease (31)
Neuropsychiatric disorders (5)
Neuroscience (292)
NextGen: Class of 2026 (358)
Non-profit (83)
Now hiring (1)
Obesity (28)
Opinion (2)
Ovarian cancer (23)
Pain (20)
Pancreatic cancer (17)
Parkinson's disease (37)
Partnered (3)
Patents (60)
Patient recruitment (55)
Peanut (1)
People (6654)
Pharmaceutical (2)
Pharmacy benefit managers (4)
Phase 1 (2798)
Phase 2 (3945)
Phase 3 (3324)
Pipeline (690)
Policy (17)
Postmarket research (262)
Preclinical (948)
Press Release (3)
Prostate cancer (23)
Psychedelics (1)
Radiopharmaceuticals (24)
Rare diseases (92)
Real estate (715)
Recruiting (1)
Regulatory (3216)
Reports (8)
Research institute (160)
Resumes & cover letters (3)
RNA editing (2)
RSV (3)
Schizophrenia (19)
Series A (34)
Series B (25)
Service/supplier (2)
Sickle cell disease (8)
Special edition (2)
Spinal muscular atrophy (7)
Sponsored (3)
Startups (522)
Stomach cancer (1)
Supply chain (14)
Tariffs (2)
The Weekly (2)
Vaccines (53)
Venture capital (9)
Weight loss (8)
Women's health (4)
Date
Today (5)
Last 7 days (67)
Last 30 days (276)
Last 365 days (3444)
2026 (352)
2025 (3417)
2024 (4163)
2023 (4933)
2022 (8446)
2021 (7879)
2020 (7035)
2019 (4570)
2018 (3513)
2017 (4184)
2016 (3695)
2015 (4579)
2014 (3399)
2013 (2892)
2012 (3024)
2011 (3157)
2010 (2945)
Location
Africa (100)
Alabama (3)
Arizona (11)
Asia (22711)
Australia (2506)
California (1114)
Canada (419)
China (393)
Colorado (8)
Connecticut (30)
Delaware (19)
Europe (14182)
Florida (94)
Georgia (13)
Idaho (1)
Illinois (39)
India (35)
Indiana (16)
Japan (246)
Kansas (5)
Louisiana (1)
Maine (4)
Maryland (161)
Massachusetts (698)
Michigan (11)
Minnesota (39)
Missouri (3)
Nebraska (2)
Nevada (10)
New Hampshire (1)
New Jersey (450)
New Mexico (1)
New York (266)
North Carolina (107)
Northern California (480)
Ohio (3)
Oklahoma (1)
Oregon (1)
Pennsylvania (172)
Rhode Island (1)
South America (116)
Southern California (480)
Tennessee (1)
Texas (77)
United States (3427)
Utah (26)
Virginia (45)
Washington D.C. (5)
Washington State (64)
Wisconsin (9)
84,565 Results for "tilt biotherapeutics ltd".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
TILT Biotherapeutics Announces Closing of USD 25 Million Series B Financing
May 13, 2025
·
4 min read
TILT Biotherapeutics Presents Clinical Data on TILT-123 in Ovarian Cancer at ASCO 2024
TILT Biotherapeutics, a clinical-stage biotechnology company developing cancer immunotherapies, announces that it will present two abstracts at the American Society of Clinical Oncology Annual Meeting 2024.
May 28, 2024
·
4 min read
Press Releases
Northwest Biotherapeutics Announces That Its Acquisition of Advent BioServices Ltd. Has Closed
October 27, 2025
·
5 min read
Government
Second MAHA Report Emphasizes Chronic Disease, Tilts at Vaccine Reform
In a livestreamed meeting Tuesday afternoon, Health Secretary Robert F. Kennedy Jr. drew a dark portrait of the state of America’s health while addressing the MAHA Commission’s most recent report, which includes plans to research potential links between vaccines and rising rates of chronic disease.
September 9, 2025
·
3 min read
·
Heather McKenzie
TILT Biotherapeutics Presents Clinical Data on TILT-123 in Combination with KEYTRUDA® (pembrolizumab) for Ovarian Cancer at AACR 2024
TILT Biotherapeutics, a clinical-stage biotechnology company developing cancer immunotherapies presented promising preliminary safety and efficacy data from their ongoing Phase I clinical trial in platinum resistant or refractory ovarian cancer patients at the American Association for Cancer Research Annual Meeting 2024.
April 10, 2024
·
4 min read
Press Releases
Northwest Biotherapeutics Announces Agreement to Acquire Advent BioServices Ltd.
August 28, 2025
·
5 min read
TILT Biotherapeutics Announces Positive Clinical Data on Lead Asset TILT-123 at Society for Immunotherapy of Cancer 2023
TILT Biotherapeutics presented Phase I data on its TILT-123 monotherapy, a T-cell activating oncolytic virus for advanced solid tumor patients, in a late-breaking poster at the Society for Immunotherapy of Cancer 2023 conference.
November 6, 2023
·
4 min read
TILT Biotherapeutics Awarded USD 2M Grant from US Department of Defense for Ovarian Cancer Immunotherapy Research
TILT Biotherapeutics announces it has been selected by the U.S. Department of Defense, America’s largest government agency, to receive a USD 2M grant for a three-year project on treatment for ovarian cancer using the company’s TILT-123 asset.
February 14, 2024
·
4 min read
Press Releases
TILT Biotherapeutics Presents Clinical Data on TILT-123 After Fully Intravenous Delivery Regimen at ESMO 2024
September 9, 2024
·
3 min read
Press Releases
TILT Biotherapeutics Provides Update on International Clinical Trial Progress with Intravenous Delivery Regimen for Cancer Immunotherapies
December 5, 2024
·
3 min read
1 of 8,457
Next
